TICKERNERD
Menu
MDGLMDGLHealthcare · Biotechnology

MDGL Stock Forecast: Madrigal Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$496
+0.57% on the day

The 19 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. hold a median 12-month price target of $661 — +33.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 5 Oct 2026 — in the upper half.

Market cap
$11.5B
Ticker Nerd rank
68 / 100
Median analyst target
$661
Analysts covering
19
Revenue$364.3M+71.2% y/y
Operating income−$56.3M
Net income−$57.9M
Free cash flow$19.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.5%
1M
−8.2%
YTD
−14.7%
1Y
+12.2%
From 52W high
−17.6%
From 52W low
+20.4%
$412
$603
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MDGL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Madrigal Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Value
93
Quality
86
Revisions
82
Momentum
64
Growth
45
Accruals
40
Size
14
Issuance
13

Volatility (97): The share price has been relatively steady.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MDGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800$900$1,000Jan 26Apr 26Jul 26Oct 26MDGLHigh $962Median $661Low $543

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
18 Buy1 Hold0 Sell
Low $543Median $661High $962

The green dot is the last close — the median target sits +33.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
24 Sept 2026Goldman SachsReinstatesBuy$704
23 Sept 2026CitigroupInitiatesBuy$725
4 Aug 2026Wolfe ResearchUpgradeOutperform$605
4 Aug 2026Wolfe ResearchUpgradeOutperform—
3 Aug 2026BarclaysMaintainsOverweight$964 → $962
3 Aug 2026BarclaysMaintainsOverweight—
29 July 2026Canaccord GenuityMaintainsBuy$578 → $587
29 July 2026Canaccord GenuityMaintainsBuy—
27 July 2026Wells FargoInitiatesOverweight$685
27 July 2026Wells FargoInitiatesOverweight—
11 June 2026B of A SecuritiesMaintainsNeutral$550 → $542
11 June 2026B of A SecuritiesMaintainsNeutral—
13 May 2026Truist SecuritiesMaintainsBuy—
7 May 2026Canaccord GenuityMaintainsBuy—
7 May 2026Evercore ISI GroupMaintainsOutperform—
6 May 2026HC Wainwright & Co.ReiteratesBuy—
20 Feb 2026B of A SecuritiesMaintainsNeutral—
28 Jan 2026BarclaysInitiatesOverweight—
20 Jan 2026CitizensMaintainsMarket Outperform—
19 Dec 2025Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDGL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MDGL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Madrigal Pharmaceuticals, Inc. returned +12.2% against +16.6% for the S&P 500, dividends included.

MDGL vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26MDGLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MDGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Madrigal Pharmaceuticals, Inc. (MDGL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−38.9×

Cheaper than 98% of US stocks

Price / sales
9.0×

Cheaper than 15% of US stocks

Price / book
22.0×

Cheaper than 4% of US stocks

EV / EBITDA
−34.4×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
71.2%

Higher than 90% of US stocks

Earnings growth (YoY)
71.2%

Higher than 80% of US stocks

Gross margin
89.0%

Higher than 96% of US stocks

Operating margin
−15.5%

Higher than 22% of US stocks

Net margin
−25.3%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−53.3%

Higher than 21% of US stocks

Return on assets
−17.8%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Madrigal Pharmaceuticals, Inc. (MDGL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Madrigal Pharmaceuticals, Inc. has a market value of $11.5B and an enterprise value of $11.0B.

  • Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 71.2% year on year.

  • Net income over the same four quarters: −$325.1M, a −25.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−12.89.

  • Free cash flow in the twelve months to 30 June 2026: −$209.3M.

  • Shares outstanding: 23.1M.

  • Trailing P/E: −38.9×; forward P/E: 51.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Madrigal Pharmaceuticals, Inc. employs 915 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

MDGL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MDGLMadrigal Pharmaceuticals, Inc.$11.5B
68
TECHBio-Techne Corp.$11.3B
94
BMRNBioMarin Pharmaceutical, Inc.$11.1B
61
IBRXImmunityBio, Inc.$10.9B
54
PCVXVaxcyte, Inc.$10.5B
54
HALOHalozyme Therapeutics, Inc.$12.3B
97
BBIOBridgeBio Pharma, Inc.$12.8B
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Madrigal Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MDGL news & analysis

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

GlobeNewsWire · 6 Oct 2026positive

Madrigal announced publication in the Journal of Hepatology of a pre-specified secondary analysis of the Phase 3 MAESTRO-NASH trial. The analysis found Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression.

Why it matters — The findings address whether common MASH genetic risk variants affected patient response to Madrigal’s Rezdiffra.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 16 Sept 2026neutral

Madrigal Pharmaceuticals granted equity inducement awards to 27 new non-executive employees on September 1 and September 14, 2026, under its 2025 Inducement Plan. The awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — A MDGL watcher would care because these inducement grants signal the company is hiring new employees, potentially expanding its team as it advances its MASH-focused biopharmaceutical pipeline.

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Madrigal Pharmaceuticals, Inc. presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with the presentation transcript published by Seeking Alpha. The event featured the company's participation at the investor conference.

Why it matters — MDGL watchers would care because the presentation provides insight into the company's business and strategy as communicated to investors at a major healthcare conference.

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

The Motley Fool · 10 Sept 2026positive

An article notes that Madrigal Pharmaceuticals' only commercial drug, Rezdiffra, continues to grow sales, and that institutional investors hold more than 95% of the company's stock float.

Why it matters — A MDGL watcher would care because continued sales growth of its sole commercial product and heavy institutional ownership provide indicators of investor confidence and commercial momentum.

Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

Madrigal Pharmaceuticals announced it will participate in the 2026 Cantor Global Healthcare Conference on Thursday, September 2026. The announcement was made on September 2, 2026, and comes from the company's Conshohocken, Pennsylvania headquarters.

Why it matters — A company's participation in a major healthcare conference provides a venue for MDGL to present its business and engage with investors and industry peers, which watchers may follow for potential updates.

FAQ

Frequently asked questions about MDGL stock

What is the MDGL stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. have a median 12-month price target of $661, with estimates ranging from $543 to $962. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDGL stock a buy right now?

Of the 19 analysts covering Madrigal Pharmaceuticals, Inc., 18 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Madrigal Pharmaceuticals, Inc. 68 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDGL?

As at 5 Oct 2026, Madrigal Pharmaceuticals, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will MDGL stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +33.1% from the last close, and Ticker Nerd's factor model ranks Madrigal Pharmaceuticals, Inc. 68 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDGL stock forecast for 2030?

No analyst covering Madrigal Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $543 to $962 over the next 12 months.

How has MDGL stock performed over the past year?

Madrigal Pharmaceuticals, Inc. returned +12.2% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Madrigal Pharmaceuticals, Inc. do?

Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need.

What is the latest news on MDGL?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants". Madrigal announced publication in the Journal of Hepatology of a pre-specified secondary analysis of the Phase 3 MAESTRO-NASH trial. The analysis found Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression.

Company

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead product, Rezdiffra, is a once-daily oral therapy designed to address the underlying biology of MASH in adults with moderate to advanced liver fibrosis. The company’s current business is centered on liver disease, with a commercial presence supported by medical affairs, patient support, and market access activities. Madrigal Pharmaceuticals Inc. also maintains research and clinical development efforts around thyroid hormone receptor-beta science, reinforcing its role as a specialist company in hepatology and metabolic medicine. Based in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals Inc. serves a focused segment of the biopharmaceutical market that targets chronic liver and metabolic disorders.

CEO Mr. William J. Sibold · 915 employees · United States · https://www.madrigalpharma.com